Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

AIMS: The AleCardio trial aimed to characterize the efficacy and safety of peroxisome proliferator‐activated receptor‐αγ agonist aleglitazar in patients with type 2 diabetes mellitus and acute coronary syndrome. The trial terminated early because of futility and safety signals. We evaluated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Koomen, Jeroen V., Heerspink, Hiddo J. L., Schrieks, Ilse C., Schwartz, Gregory G., Lincoff, A. Michael, Nicholls, Stephen J., Svensson, Anders, Wedel, Hans, Weichert, Arlette, Grobbee, Diederick E., Stevens, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916612/
https://www.ncbi.nlm.nih.gov/pubmed/31468659
http://dx.doi.org/10.1111/dom.13862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916612/
https://www.ncbi.nlm.nih.gov/pubmed/31468659
http://dx.doi.org/10.1111/dom.13862

Ejemplares similares